Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3426825 | 0.92 | NLRP3 (0.51) | MAOBSMN1; SMN2NOTUMMEN1KMT2A | |
| SCHEMBL3399234 | 0.90 | MAOB (0.56) | MAOBSMN1; SMN2NOTUMMEN1KMT2A | |
| SCHEMBL3428012 | 0.90 | MAOB (0.53) | MAOBSMN1; SMN2NOTUMMEN1KMT2A | |
| SCHEMBL3427692 | 0.88 | MAOB (0.48) | MAOBSMN1; SMN2NOTUMMEN1KMT2A | |
| SCHEMBL3429088 | 0.86 | SMN1; SMN2 (0.64) | MAOBSMN1; SMN2NOTUMMEN1KMT2A | |
| SCHEMBL4293837 | 0.85 | MAOB (0.55) | MAOBSMN1; SMN2NOTUMMEN1KMT2A | |
| SCHEMBL3400379 | 0.84 | MAOB (0.53) | MAOBSMN1; SMN2NOTUMMEN1KMT2A | |
| SCHEMBL3430120 | 0.84 | MAOB (0.54) | MAOBSMN1; SMN2NOTUMMEN1KMT2A | |
| SCHEMBL3427907 | 0.83 | MAOB (0.53) | MAOBSMN1; SMN2NOTUMMEN1KMT2A | |
| SCHEMBL3426441 | 0.83 | RAB9A (0.50) | MAOBSMN1; SMN2MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250162-B1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2014-03-19 | — | — | EP | claimed |
| US-8536221-B2 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBVIE INC. (US) | 2013-09-17 | — | — | US | claimed |
| CN-101990537-A | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBOTT LAB | 2011-03-23 | — | — | CN | claimed |
| EP-2250162-A2 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2010-11-17 | — | — | EP | claimed |
| US-20090270408-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-10-29 | — | — | US | claimed |
| WO-2009100294-A2 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-08-13 | — | — | WO | claimed |
| EP-2250162-B1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2014-03-19 | — | — | EP | disclosed |
| US-8536221-B2 | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBVIE INC. (US) | 2013-09-17 | — | — | US | disclosed |
| CN-101990537-A | Amide derivatives as positive allosteric modulators and methods of use thereof | ABBOTT LAB | 2011-03-23 | — | — | CN | disclosed |
| US-20090270408-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270408-A1 | AMIDE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS AND METHODS OF USE THEREOF | CHRNA2, CHRNA4, CHRNA5 | MAOB 2525/4885SMN1; SMN2 960/4885NOTUM 3157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.